On Septembr 24, 2019, Hoag Memorial Hospital Presbyterian, in Orange County, California, announced the start of a research study to identify and characterize potential early disease markers for cancer diagnostics, cancer progression, and treatment resistance. In partnership with Exosome Sciences (https://www.exosomesciences.com/, a subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD) (https://www.aethlonmedical.com/), scientists will study exosomes in cancer patients and individuals at high genetic risk for cancer (https://www.hoag.org/specialties-services/cancer/conditions/hereditary-cancer/). Exosomes are nanoparticles that are abundantly released from cancer cells and can provide a snapshot of a tumor’s genetic and protein cargo, making them important targets for non-invasive liquid biopsies in cancer. “Liquid biopsies have the potential to facilitate the early detection of cancer and the assessment of the efficacy of potential treatments in real time. This may prove to be a critical tool in our ongoing efforts to help patients with cancer,” said Michael Demeure, MD, Program Director of Precision Medicine at Hoag (https://www.hoag.org/specialties-services/cancer/treatments-services/precision-medicine/) and the principal investigator on the study at Hoag. “Hoag has an active Hereditary Cancer Program (https://www.hoag.org/specialties-services/cancer/conditions/hereditary-cancer/) that supports a number of individuals and families at high risk of developing cancer and is committed to achieving breakthroughs in the detection of cancer at its earliest possible and most treatable stage.” “Liquid biopsies are a rapidly developing field of non-invasive tests for patients with and at risk for cancer,” said Timothy Rodell, MD, CEO of Exosome Sciences and Aethlon Medical, Inc.
Login Or Register To Read Full Story